New frontier in liver cancer treatment: Oncolytic viral therapy - Vilarinho - 2014 - Hepatology - Wiley Online Library
The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma in: Neurosurgical Focus Volume 50 Issue 2 (2021) Journals
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy - ScienceDirect
JX-594 is selectively delivered to, and amplified within, tumours after... | Download Scientific Diagram
Full article: Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Jennerex and Transgene announce initiation of clinical trial in metastatic colon cancer with intravenous JX-594
Frontiers | Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment | Immunology
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF - ScienceDirect
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer | Journal for ImmunoTherapy of Cancer
PDF) A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Pexa-Vec (JX-594) | SILLAJEN
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics | Journal for ImmunoTherapy of Cancer | Full Text
The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets | Journal of Experimental & Clinical Cancer Research | Full Text
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy: Molecular Therapy
Biomedicines | Free Full-Text | Oncolytic Virotherapy for Cancer: Clinical Experience | HTML
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF: Molecular Therapy
Frontiers | Delivery and Biosafety of Oncolytic Virotherapy | Oncology
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF - ScienceDirect
Oncolytic virus therapy: A new era of cancer treatment at dawn - Fukuhara - 2016 - Cancer Science - Wiley Online Library
Selected application schemes of JX-594 (a-f): (a) published by Heo et... | Download Scientific Diagram
Viruses as nanomedicine for cancer | IJN
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy - ScienceDirect
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma: Molecular Therapy
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial - The Lancet Oncology
